Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
CD200 expression in patients with Multiple Myeloma: another piece of the puzzle
Concetta Conticello1, Raffaella Giuffrida, Nunziatina Parrinello
1Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), Viagrande, Catania, Italy.
Abstract:
CD200 is a relatively ubiquitously expressed molecule that plays a role in cancer immune evasion through interaction with its receptors. High expression levels of CD200 have been described in different human malignancies. For example, CD200 has been shown to be targeted after RAS/RAF/MEK/ERK activation in melanoma. Here we present the analysis of CD200 expression in human Multiple Myeloma (MM) samples. We found that CD200-positive cells express ERK and p-ERK. Moreover, UO126, a MEK inhibitor, reduces CD200 expression. Furthermore, we observe that CD200-positive cells show reduced immunogenicity compared to normal lymphocytes and that such immunogenicity increases when UO126 is used. We therefore hypothesize that CD200 expression in MM could suppress antitumor response and that anti-CD200 treatment might be therapeutically beneficial in CD200-expressing tumors.
Insights
CD200 expression in Multiple Myeloma (MM) correlates with immune evasion. Inhibiting MEK with UO126 reduces CD200 and enhances immune response, suggesting anti-CD200 therapy could benefit MM patients.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- CD200 is a molecule involved in cancer immune evasion.
- High CD200 expression is observed in various human cancers.
- CD200 targeting has been explored in melanoma following RAS/RAF/MEK/ERK pathway activation.
Purpose of the Study:
- To analyze CD200 expression in human Multiple Myeloma (MM) samples.
- To investigate the relationship between CD200, the ERK pathway, and immune evasion in MM.
- To evaluate the therapeutic potential of targeting CD200 in MM.
Main Methods:
- Analysis of CD200 expression in human MM samples.
- Assessment of ERK and p-ERK expression in CD200-positive cells.
- Treatment of cells with UO126, a MEK inhibitor, to observe effects on CD200 expression.
- Evaluation of immunogenicity of CD200-positive cells and the impact of UO126.
Main Results:
- CD200-positive cells in MM express ERK and p-ERK.
- The MEK inhibitor UO126 reduces CD200 expression in MM.
- CD200-positive cells exhibit reduced immunogenicity compared to normal lymphocytes.
- UO126 treatment increases the immunogenicity of CD200-positive cells.
Conclusions:
- CD200 expression in MM is linked to the ERK pathway.
- CD200 contributes to immune evasion in Multiple Myeloma.
- Targeting CD200 may represent a potential therapeutic strategy for MM patients with CD200-expressing tumors.
